Quality of Life in Adult Patients Treated with Peripheral Blood Progenitor Cell Transplantation: the Effect of Selected Psychosocial, Demographics and Health Aspects on Quality of Life: a Retrospective Analysis

Acta Medica (Hradec Králové)
L SlovacekVladimír Pavlík


this retrospective study analyses the effect of selected psychosocial, demographics and health aspects on quality of life (QoL) in adult patients treated with peripheral blood progenitor cell transplantation (PBPCT). The total number of respondents treated with PBPCT between the years 2001-2003 was 95. The return rate of QoL questionnaires was 72.1 % (71 respondents). There were 100 % ratable QoL questionnaire. The average age of all respondents was 55.5 years old. The Czech version of an international generic European Quality of Life Questionnaire - Version EQ-5D was used. The effect of selected aspects on QoL of patients was determined by analysis of variance. The QoL questionnaires were evaluated with descriptive analysis. The above-mentioned aspects proved statistically significant dependence of QoL (EQ-5D score - QoL dimensions, EQ-5D VAS - subjective health condition) on age, increasing number of associated diseases, religion and type of disease. The effect of other aspects on QoL was not proven statistically significant. The QoL in adult patients treated with PBPCT declines with increasing age and with the increasing number of associated diseases. People of faith have a higher level of QoL than non-believers. Patients wi...Continue Reading


Dec 1, 1992·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M GrantS J Forman
Sep 21, 2000·British Journal of Haematology·S ChiodiA Bacigalupo
Oct 11, 2001·Bone Marrow Transplantation·H HeinonenT Ruutu
Sep 4, 2004·Psychosomatics·Grace ChangJoseph H Antin
Jan 19, 2005·European Journal of Haematology·C A Uyl-de GrootP C Huijgens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.